Caplin Point gets approval for sterile injectables from Colombia
Caplin Point gets approval for sterile injectables from Colombia

Caplin Point gets approval for sterile injectables from Colombia

Nidhi Jani Article rating: 5.0

The company is hoping that this approval would help to further expand its footprints in Latin America. The company’s Unit 1 is currently catering to emerging markets of Latin America and Africa with a variety of dosage forms such as tablets, capsules, softgel capsules, suppositories, liquid orals and topicals.

Should NRIs buy life insurance in India?
Should NRIs buy life insurance in India?

Should NRIs buy life insurance in India?

DSIJ Intelligence Article rating: 5.0

FEMA (Foreign Exchange Management Act) allows NRIs to buy any type of insurance in India. So, should you as an NRI buy one? Let’s find out.

Pennar group gets orders amounting to Rs 311cr
Pennar group gets orders amounting to Rs 311cr

Pennar group gets orders amounting to Rs 311cr

Nidhi Jani Article rating: 5.0

On Monday, Pennar group informed the bourses that it has received orders worth Rs. 311 crore for the month of April across its various business verticals.


Cadila gets USFDA approval for Chlorthalidone tablets
Cadila gets USFDA approval for Chlorthalidone tablets

Cadila gets USFDA approval for Chlorthalidone tablets

Nidhi Jani Article rating: 5.0

Chlorthalidone tablets are used to treat hypertension. These are also used to reduce extra salt and water in the body caused by conditions such as heart failure, liver disease, and kidney disease.

Ten stocks close to their 52-weeks high
Ten stocks close to their 52-weeks high

Ten stocks close to their 52-weeks high

Shital Jibhe Article rating: 5.0

The markets on May 13, 2019 opened gap down. BSE Sensex is trading at 37,477.56, up by 14.57 points and the Nifty is trading at 11,267.20, down by 11.70 points. 

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

Shital Jibhe Article rating: 5.0

Overall volumes in futures & options currently stand at 1.00 crore contracts with a turnover of Rs. 6,73,089.52 crore.

RSS
First34603461346234633465346734683469Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR